Tumor Volume-Adapted RT Leads to Good Lung Cancer Control With Low Toxicity No recurrence at 1 year in 90% of cases with primary tumors, metastases, synchronous disease Nov 02, 2021
Targeted RT Boosts PFS in Oligoprogressive Lung Cancer Fivefold improvement in NSCLC but no benefit in oligoprogressive breast cancer Oct 25, 2021
'You're Still Doing WHAT After Lung Cancer Surgery?!' But don't give up on hardened smokers, researcher urges Oct 19, 2021
Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCs Oral tyrosine kinase inhibitor may serve patient population with high unmet need Oct 14, 2021
Immunotherapy Combo Fails to Boost Survival in Limited-Disease SCLC No PFS or OS improvement with consolidation nivolumab-ipilimumab after standard treatment Sep 29, 2021
Radiation or Surgery in Early Lung Cancer: Does It Make a Difference? Ablative radiation still noninferior to VATS after longer follow-up Sep 24, 2021
How Many Deaths Will New Cigarette Warnings Prevent? Modeling study comes up with big numbers Sep 24, 2021
Top Science From the World Conference on Lung Cancer In this podcast, we examine some of the most important studies presented at this year's meeting Sep 23, 2021 podcast
Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer More than half of patients responded to antibody-drug conjugate targeting HER2 Sep 19, 2021
More Help on the Way for Lung Cancers With Exon 20 Mutations? Early trials of DZD9008 demonstrated responses in over a third of patients Sep 15, 2021
Cancer Vaccine May Boost Anti-EGFR Efficacy in Non-Small Cell Lung Cancer More than 90% disease control rate, hint of improved PFS in pilot trial Sep 14, 2021
Novel ADC Promising in Certain Non-Squamous Lung Cancers Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression Sep 14, 2021
More Data in Support of Surgery for Malignant Pleural Mesothelioma Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone Sep 13, 2021
Meta-Analysis Confirms Benefits of Low-Dose CT Screening for Lung Cancer LDCT associated with a 16% relative reduction in mortality versus no screening Sep 13, 2021
Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer Sep 12, 2021
Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesothelioma Atezolizumab add-on offers promising outcomes in phase I trial Sep 12, 2021
Durable Response with Immunotherapy Combos in NSCLC with Brain Metastases Analysis of CheckMate 9LA data and phase II study from Spain offer hope in advanced disease Sep 12, 2021
Dual Immunotherapy Boosts Survival in Metastatic NSCLC Benefit with durvalumab-tremelimumab may vary by PD-L1 expression, histology Sep 10, 2021
Study Sheds Light on Physician-Assisted Suicide in Lung Cancer Patients Patients often did not consult with radiation or medical oncologists Sep 09, 2021
Second-Line Combo Fails to Improve Survival in SCLC No OS difference, but lurbinectedin-doxorubicin was less toxic than standard chemotherapy options Sep 09, 2021
High Response Rate in Non-Small Cell Lung Cancer With RET Inhibitor Responses in 66-80% of patients from China confirm activity of pralsetinib Sep 09, 2021
TROP2 Antibody-Drug Conjugate Shows Promise in Lung Cancer Disease control observed in over two-thirds of patients at selected dose Sep 08, 2021
Another Ivermectin Flop; 'Instant' Lung Cancer Decision Tool; Triple COPD Tx & Death Highlights from the European Respiratory Society virtual meeting Sep 08, 2021
No Survival Bump With PARP Inhibitor in Squamous NSCLC Possible benefit in tumors with positive lung cancer-specific gene panel Sep 07, 2021
Negative Trials Close the Book on Once-Promising SCLC Drug Poor tolerability doomed rovalpituzumab tesirine regimens in four clinical trials Sep 07, 2021
AI Blood Test Proves Useful in Lung Cancer Detection Such an approach would be useful considering the barriers to LDCT among high-risk people Aug 25, 2021
Avoiding Hippocampus in Brain RT May Help Preserve Cognitive Function Recall metrics favored hippocampal avoidance at all time points, with no increase in brain mets Aug 13, 2021
Drug Combo Promising in Rare Mesothelioma Small study showed "robust and durable" responses, with "meaningful prolongation of survival" Jul 19, 2021
Juul Bought Out Medical Journal for $51K E-cig maker sponsored nearly a dozen studies, took over journal as it awaits FDA ruling Jul 13, 2021
LDCT Screening Linked to Lower Risk of Brain Mets in Lung Cancer This observed reduction in risk may be due to a less aggressive tumor biology, said study author Jun 28, 2021
Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
Bispecific Antibody Active in NRG1-Positive Pancreatic Cancer Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors Jun 10, 2021
Combination Shows Promise in Post-Osimertinib Lung Cancer Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
Antibody-Drug Conjugate Active in Resistant Lung Cancer Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLC PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
Lymph Node Findings on PET: Cancer or COVID Vaccine? Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
Anti-PD-L1 Plus SBRT Enhances Major Responses in Early NSCLC Neoadjuvant combo needs to be validated in a larger randomized trial May 20, 2021
PD-L1 Inhibitor Thwarts Recurrence in Early Lung Cancer Risk of death, recurrence 34% lower with atezolizumab after surgery and chemo May 19, 2021
Op-Ed: Is FDA's Cigarette Ban Just Smoke and Menthols? Actually implementing a ban on menthol cigarettes and cigars could take years May 03, 2021
